OA08 JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications

Autor: Christopher Stovin, Mark D Russell, Edward Alveyn, Olukemi Adeyemi, Vishit Patel, Maryam A Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P Cope, James B Galloway

Publikováno v: Rheumatology. 62

Background/Aims Concerns have been raised about the risk of malignancy with Janus kinase inhibitors (JAKi) following the ORAL Surveillance study, which reported an increased incidence of malignancy with tofacitinib compared with Tumor Necrosis Factor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f835d7ba7e8459c04e794570a16eb3ce
https://doi.org/10.1093/rheumatology/kead104.008

Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY

Autor: Mark D Russell, James B Galloway, Colm D Andrews, Brian MacKenna, Ben Goldacre, Amir Mehrkar, Helen J Curtis, Ben Butler-Cole, Thomas O'Dwyer, Sumera Qureshi, Joanna M Ledingham, Arti Mahto, Andrew I Rutherford, Maryam A Adas, Edward Alveyn, Sam Norton, Andrew P Cope, Katie Bechman

Publikováno v: The Lancet. Rheumatology. 4(12)

The impact of the COVID-19 pandemic on the incidence and management of inflammatory arthritis is not understood. Routinely captured data in secure platforms, such as OpenSAFELY, offer unique opportunities to understand how care for patients with infl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f33d30a79e4297c2ba65035ea9bbc54
https://pubmed.ncbi.nlm.nih.gov/36466787

Treat-to-target urate-lowering therapy and hospitalisations for gout: results from a nationwide cohort study in England

Autor: Mark D Russell, Edward Roddy, Andrew I Rutherford, Benjamin Ellis, Sam Norton, Abdel Douiri, Martin C Gulliford, Andrew P Cope, James B Galloway

Publikováno v: Rheumatology (Oxford, England).

Objective To investigate associations between treat-to-target urate-lowering therapy (ULT) and hospitalizations for gout. Methods Using linked Clinical Practice Research Datalink and NHS Digital Hospital Episode Statistics data, we described the inci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e786ba5cee6ccb65185d072f8fb611
https://pubmed.ncbi.nlm.nih.gov/36355461

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications

Autor: Mark D Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P Cope, James B Galloway

Publikováno v: Annals of the Rheumatic Diseases. :ard-2023

ObjectivesTo estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate.MethodsSystematic searches of databases were performed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24b8850b7abaf48a7b2a2c20e279f13c
https://doi.org/10.1136/ard-2023-224049

Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Autor: Sam Norton, James Galloway, Elena Nikiphorou, Mariam Molokhia, Katie Bechman, Andrew I Rutherford, Andrew P. Cope, Kimme L. Hyrich, Benjamin D Clarke, Mark Yates

Publikováno v: British Society for Rheumatology Biologics Register, Bechman, K, Clarke, B D, Rutherford, A I, Yates, M, Nikiphorou, E, Molokhia, M, Norton, S, Cope, A P, Hyrich, K & Galloway, J B 2019, ' Polypharmacy is associated with treatment response and serious adverse events : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis ', Rheumatology (Oxford), vol. 58, no. 10, pp. 1767-1776 . https://doi.org/10.1093/rheumatology/kez037

Objective To evaluate whether polypharmacy is associated with treatment response and serious adverse events (SAEs) in patients with RA using data from the British Society for Rheumatology Biologics Register (BSRBR-RA). Methods The BSRBR-RA is a prosp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c67e2e7725632e409fc751308b534e9
https://doi.org/10.1093/rheumatology/kez037